Knott David M Jr Purchases Shares of 420,000 Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL)

Key Points

• David M Knott Jr has acquired a significant stake of 420,000 shares in Autolus Therapeutics, valued at approximately $651,000, making up about 0.16% of the company's stock.
• Institutional investors hold 72.83% of Autolus Therapeutics' shares, indicating strong interest from hedge funds and investment firms.
• Analysts maintain a positive outlook with a consensus rating of "Buy" for AUTL, and a price target averaging $9.32 per share.

Knott David M Jr acquired a new stake in shares of Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL - Free Report) in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 420,000 shares of the company's stock, valued at approximately $651,000. Knott David M Jr owned about 0.16% of Autolus Therapeutics as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also modified their holdings of AUTL. Virtus ETF Advisers LLC boosted its position in shares of Autolus Therapeutics by 29.9% in the 4th quarter. Virtus ETF Advisers LLC now owns 26,429 shares of the company's stock valued at $62,000 after purchasing an additional 6,081 shares during the period. Barclays PLC lifted its position in shares of Autolus Therapeutics by 1,094.3% in the 4th quarter. Barclays PLC now owns 11,859 shares of the company's stock valued at $28,000 after acquiring an additional 10,866 shares in the last quarter. Jane Street Group LLC acquired a new position in Autolus Therapeutics in the 4th quarter worth approximately $26,000. Invesco Ltd. grew its position in Autolus Therapeutics by 53.3% during the 1st quarter. Invesco Ltd. now owns 32,738 shares of the company's stock worth $51,000 after purchasing an additional 11,381 shares in the last quarter. Finally, Two Sigma Advisers LP raised its stake in Autolus Therapeutics by 4.8% during the 4th quarter. Two Sigma Advisers LP now owns 333,400 shares of the company's stock valued at $783,000 after purchasing an additional 15,400 shares during the period. 72.83% of the stock is currently owned by institutional investors and hedge funds.

Autolus Therapeutics Stock Performance

Shares of AUTL opened at $2.33 on Monday. The company has a market capitalization of $620.11 million, a PE ratio of -2.65 and a beta of 1.90. The company's 50 day moving average price is $2.33 and its 200 day moving average price is $1.90. Autolus Therapeutics PLC Sponsored ADR has a 52 week low of $1.11 and a 52 week high of $5.00.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.02). The firm had revenue of $8.98 million for the quarter, compared to analyst estimates of $1.59 million. On average, equities analysts forecast that Autolus Therapeutics PLC Sponsored ADR will post -0.94 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Needham & Company LLC reiterated a "buy" rating and set a $10.00 price target on shares of Autolus Therapeutics in a report on Monday, July 21st. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has a consensus rating of "Buy" and an average price target of $9.32.

Autolus Therapeutics Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.